Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Molecular marker for diagnosing pelvic prolapse

A molecular marker and pelvic prolapse technology, applied in the field of biomedicine, can solve problems such as radical disease and unclear pathogenesis

Active Publication Date: 2018-06-15
QINGDAO MEDINTELL BIOMEDICAL CO LTD
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, due to its unclear pathogenesis, most of the current treatments only treat the symptoms, but cannot cure the disease from the etiology.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Molecular marker for diagnosing pelvic prolapse
  • Molecular marker for diagnosing pelvic prolapse
  • Molecular marker for diagnosing pelvic prolapse

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0050] Example 1 Collection of Cases

[0051] From September 2012 to December 2013, a total of 9 POP patients who visited the Department of Obstetrics and Gynecology of Union Medical College Hospital were collected. A total of 3 cases were collected using age and place of residence as matching factors. The uterosacral ligament tissue samples of all subjects were obtained, numbered and stored in a -80°C low-temperature refrigerator.

[0052] Inclusion criteria for POP group: a. POP-Q score ≥ II degree after gynecological examination;

[0053] b. Continuously living in the Beijing area;

[0054] c. At least one childbirth history.

[0055] Exclusion criteria: a. Patients who received hormone replacement therapy in the past 3 months;

[0056] b. Patients with connective tissue diseases (rheumatoid arthritis, systemic lupus erythematosus, polymyositis, Marfan syndrome, Eydown syndrome);

[0057] c. Pregnant patients;

[0058] d. The patient refuses to join;

[0059] e. Pati...

Embodiment 2

[0071] Example 2 High-throughput sequencing and analysis

[0072] RNA extraction is performed on the tissue, followed by agarose gel electrophoresis after RNA extraction. From the results of electrophoresis, it can be preliminarily judged whether the quality of the extracted RNA sample is qualified or not, and whether it can be used for further transcriptome analysis. Then, the extraction of RNA samples was detected by NanoDrop1000 spectrophotometer, and the sample requirements for RNA-seq sequencing: OD260 / OD280 was 1.8-2.2.

[0073] The sequencing platform is the HiSeq 2500 high-throughput sequencing platform of Illumina, which performs high-throughput transcriptome deep sequencing. After sequencing, we use Fast-QC (http: / / www.bioinformatics.babraham.ac.uk / projects / fastqc / ) The software evaluates the quality of sequencing data as a whole, including base quality value distribution, quality value position distribution, GC content, PCR duplication content, kmer frequency, etc. ...

Embodiment 3

[0074] Example 3 Expression of Candidate Genes in Uterosacral Ligament Tissues of Patients with Pelvic Prolapse and Controls

[0075] 1. Materials and methods

[0076] 1. Materials

[0077] The uterosacral ligament tissues of 35 cases of pelvic prolapse patients and 5 cases of control uterosacral ligament tissues were selected and grouped and numbered. The control group was patients with benign gynecological diseases undergoing laparotomy or vaginal hysterectomy, pelvic organ prolapse was ruled out by vaginal examination, and no urinary incontinence symptoms. Among the 35 patients with pelvic cavity prolapse, 17 cases were grade II, 8 cases were grade III, and 10 cases were grade IV.

[0078] 2. Method

[0079] 2.1 Extraction of total RNA from uterosacral ligament tissues of patients with pelvic prolapse and controls

[0080] use Reagent (invitrogen, Cat. No. 15596-018) was used to extract sample RNA, and the experimental operation was performed according to the product ma...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of a molecular marker in diagnosing pelvic prolapse, in particular to application of an RPRM gene, a PCP4 gene and an expression product of the RPRM gene and the PCP4 gene in diagnosing pelvic prolapse. Based on a high flux sequencing result, a bioinformatics method is adopted to screen genes, the RPRM gene and the PCP4 gene are picked out, and further, througha molecular cell biology method, it is proved that the RPRM gene and the PCP4 gene have an obvious high expression in a pelvic prolapse tissue, can be used for preparing a preparation assisting in diagnosing pelvic prolapse and have important clinical application value.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to the application of molecular markers in the diagnosis and treatment of pelvic prolapse, and more specifically to the application of RPRM, PCP4 genes and their expression products in the diagnosis and treatment of pelvic prolapse. Background technique [0002] Pelvic organ prolapse (Pelvic organ prolapse, POP) is caused by the defect, damage or dysfunction of the pelvic floor support structure. It is a common disease that affects the quality of life of middle-aged and elderly women. and dysfunction. The clinical manifestations are prolapse of the uterus, vagina, bladder, urethra, colorectum, small intestine and other organs, often accompanied by symptoms such as urinary incontinence, urination and defecation disorders, and sexual dysfunction. Epidemiological studies have shown that up to 50% of adult women are troubled by this disease, and the incidence of both primary POP and recurren...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6883A61K45/00A61P15/00
CPCA61K48/00C12N15/11C12Q1/6883C12Q2600/158G01N33/577
Inventor 董琳杨承刚
Owner QINGDAO MEDINTELL BIOMEDICAL CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com